GlassScriptPhysician profile
Sushil K Jain
NPI 1740260041
$1,161.44
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $118 · 2021: $123 · 2022: $78.39 · 2023: $389 · 2024: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.41 |
| Entertainment | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $271.80 | 2021-2023 | Dailies Total1, Precision 1, Total30 |
| Optos, INC. | $176.44 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Shire North American Group INC | $121.66 | 2019 | |
| Sun Pharmaceutical Industries INC. | $118.02 | 2023 | Cequa |
| Maculogix, INC. | $117.92 | 2020 | |
| Sight Sciences, INC. | $111.75 | 2024 | Omni Surgical System |
| Rxsight INC | $78.39 | 2022 | |
| Carl Zeiss Meditec, INC. | $43.65 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$800,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.